Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadopentetate dimeglumine
Drug ID BADD_D00991
Description A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indications and Usage For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Marketing Status approved
ATC Code V08CA01
DrugBank ID DB00789
KEGG ID D01707
MeSH ID D019786
PubChem ID 131751658
TTD Drug ID D0RQ2W
NDC Product Code Not Available
UNII RH248G8V27
Synonyms Gadolinium DTPA | DTPA, Gadolinium | Gadolinium Diethylenetriaminepenta-acetic Acid | Diethylenetriaminepenta-acetic Acid, Gadolinium | Gadolinium Diethylenetriaminepenta acetic Acid | Gadopentetic Acid | Gd-DTPA | Gd DTPA | Gadolinium DTPA Disodium Salt | Magnograf | Magnograf Enteral | Gadopentetate Dimeglumine | Dimeglumine, Gadopentetate | Gadolinium DTPA Dimeglumine Salt | Gadolinium DTPA Dimeglumine | Dimeglumine, Gadolinium DTPA | Magnevist | Magnevist Enteral
Chemical Information
Molecular Formula C51H82O21
CAS Registry Number 55466-01-8
SMILES CC(=CC1CC(C2C3CCC4C5(CCC(C(C5CCC4(C36CC2(O1)OC6)C)(C)C)OC7C(C(C(CO7)O)OC8C(C(C(C (O8)CO)O)O)OC9C(C(C(CO9)O)O)O)OC1C(C(C(CO1)O)O)O)C)(C)O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysgeusia17.02.07.003; 07.14.03.001--
Dysphagia07.01.06.003--
Dysphonia19.19.03.002; 17.02.08.004; 22.12.03.006--
Dyspnoea02.11.05.003; 22.02.01.004--
Ear pain04.03.01.003--
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.015--
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Face oedema08.01.07.003; 23.04.01.004; 10.01.05.002--
Fatigue08.01.01.002--
Feeling cold08.01.09.008--Not Available
Feeling hot08.01.09.009--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Headache17.14.01.001--
Heart rate decreased13.14.04.001--Not Available
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypotension24.06.03.002--
Injection site reaction12.07.03.015; 08.02.03.014--
Lacrimation increased06.08.02.004--
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.003--
Laryngospasm22.04.02.002--
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.005--Not Available
Loss of consciousness17.02.04.004--Not Available
Micturition urgency20.02.02.006--
Migraine24.03.05.003; 17.14.02.001--Not Available
The 2th Page    First    Pre   2 3 4    Next   Last    Total 4 Pages